FRI0676 PREVALENCE AND UVEITIS CHARACTERISTICS OF A COHORT OF PATIENTS WITH SPONDILOARTROPATHY
Authors: Sycille Jeria, Patricia Moya, Ana Laiz, Jose Vela, Jesus Diaz, Hyesang Park, Berta Magallares, Ivan Castellví, Ana Milena Millán Arciniegas, Josep Maria Llobet, Hector Corominas
Journal: Annals of the Rheumatic Diseases (2019)

<h3>Background</h3> Uveitis can be a clinical manifestation of different systemic processes, known is the association of anterior uveitis in patients with spondyloarthritis (SpA) <h3>Objectives</h3> To describe the prevalence, characteristics and course of ocular inflammatory pathology from a cohort of patients with SpA <h3>Methods</h3> Retrospective descriptive study made in a cohort of 451 SpA patients according to the ASAS classification criteria in a a tertiary university hospital from Barcelona. Were selected patients who presented or had presented uveítis (defined according to the SUN<sup>1</sup> classification criteria) Demographic, clinical, radiological and serological data of the joint disease and characteristics of the ocular affectation were collected, as well as the treatment of both <h3>Results</h3> Of the 451 patients reviewed, 43 (9.53%) patients with a history of uveitis were included in the study. From the cohort, the average age at diagnosis of SPA was 37 (± 27) years and 38 (88.4%) had positive HLAB27. The most prevalent subtypes of SPA were Ankylosing Spondylitis (AS): 27 (62.8%) and Psoriatic Arthritis (APSo): 8 (18.6%). The characteristics of the sample are summarized in Table 1 The average age at the first uveitis outbreak was 45 ± 23 years. The anterior location was more prevalent (n: 39, 90.7%), unilateral (n: 35, 81.4%) and acute onset (n: 42, 97.6%) Two of patients with anterior uveítis had other associated complications, one had macular edema and other retinal vasculitis. The treatment of uveitis was topical corticosteroids in 39 (90.6%) patients, 2 (4.6%) treatment with oral sulfasalazine. Despite the treatment, 22 (51.2%) patients presented a recurrent course. Table 2 shows the ocular clinical features <h3>Conclusion</h3> In our cohort of SPA, prevalence of uveitis was 10%, predominantly in HLA B27 patients and axial involvement, of which 62.8% met criteria for AD and 18.6% APSO with different degrees of axial involvement, including under systemic treatment (FAMEs/Biological). The most frequently presentation was anterior, unilateral, acute and recurrent uveitis. Being the most used treatment topical corticosteroids. <h3>References</h3> [1] Am J Ophthalmol2005;140: 509-516 [2] Ann Rheum Dis. 2009;68:777-83 <h3>Disclosure of Interests</h3> Sycille Jeria: None declared, Patricia Moya: None declared, Ana Laiz Consultant for: Lilly, Novartis, AbbVvie, MSD, UCB and Janssen, Speakers bureau: Lilly, Novartis, Abvvie, MSD, UCB and Janssen, Jose Vela: None declared, Jesus Diaz: None declared, HyeSang Park: None declared, Berta Magallares: None declared, Ivan Castellví Consultant for: I received fees less than 5000USD as a consultant for Kern and Actelion, Paid instructor for: I received fees less than 2000USD as a instructor for Boehringer -Ingelheim, Novartis and Gebro, Speakers bureau: ND, Ana Milena Millán Arciniegas: None declared, Josep Maria Llobet: None declared, Hector Corominas: None declared